Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Dicerna Pharmaceutic (NQ: DRNA )

24.64 USD UNCHANGED
Streaming Delayed Price Updated: 5:01 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Dicerna Pharmaceutic

< Previous 1 2 3 4 5 6 7 8 9 Next >
Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference
Dicerna announced that Doug Fambrough will participate in two events at the H.C. Wainwright Virtual BioConnect Conference taking place Jan. 11-14. 
From Business Wire News Releases
Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
Dicerna announced that Novo Nordisk has nominated its first candidate for development under the existing agreement between the two companies. 
From Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced the Company approved the grant of inducement stock options of common stock and restricted stock units among three new employees. 
From Business Wire News Releases
Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria
Dicerna today announced the enrollment completion of the PHYOX™2 pivotal trial of nedosiran for the treatment of primary hyperoxaluria. 
From Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among six new employees. 
From Business Wire News Releases
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020
Dicerna announced positive updated Phase 1 data on its investigational GalXC™ RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV). 
From Business Wire News Releases
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement
Dicerna announced FDA acceptance of the IND Application filed by Lilly for LY3561774, clinical-stage candidate to emerge from their collaboration. 
From Business Wire News Releases
Dicerna to Participate in Upcoming Investor Conferences
Dicerna announced that Douglas M. Fambrough, Ph.D., president and CEO, will be participating in fireside chats at two upcoming investor conferences. 
From Business Wire News Releases
Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020
Dicerna will present an update on the Company’s early-stage development of extrahepatic RNAi therapeutics at TIDES Europe 2020. 
From Business Wire News Releases
Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update
Dicerna today reported its financial results for the third quarter ended Sep. 30, 2020. 
From Business Wire News Releases
WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders
WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of... 
From Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among nine new employees. 
From Business Wire News Releases
Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLD’s The Liver Meeting® Digital Experience™ 2020
Dicerna will present updated data related to RG6346, an RNAi investigational therapy, at The Liver Meeting® Digital Experience™ 2020. 
From Business Wire News Releases
Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020
Dicerna announced that it will release its Q3 2020 financial results and will provide a general business update on Thursday, Nov. 5. 
From Business Wire News Releases
Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)
Dicerna announced positive new interim data from its ongoing PHYOX3 open-label trial of nedosiran, an investigational therapy for PH1, PH2 and PH3. 
From Business Wire News Releases
Dicerna to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, Oct. 20. 
From Business Wire News Releases
VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors
From GlobeNewswire News Releases
Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020
Dicerna announced that clinical data on nedosiran, an investigational candidate for the treatment of PH, will be presented at ASN Kidney Week 2020. 
From Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among eight employees. 
From Business Wire News Releases
Dicerna to Participate in the Chardan 4th Annual Genetic Medicines Conference
Dicerna announced that Doug M. Fambrough will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Oct. 5. 
From Business Wire News Releases
Dicerna Appoints Ling Zeng as Chief Legal Officer and Secretary
Dicerna announced the hiring of Ling Zeng, Esq., as the Company's chief legal officer and secretary and a member of the executive leadership team. 
From Business Wire News Releases
Dicerna to Participate in Upcoming September Investor Conferences
Dicerna announced that the Company will be participating in four virtual investor conferences in September. 
From Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among 11 employees. 
From Business Wire News Releases
Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Techno
Dicerna presents positive clinical data for investigational treatments RG6346 for chronic HBV and Nedosiran for PH and preclinical data in new tissues 
From Business Wire News Releases
Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update
Dicerna today reported its financial results for the second quarter ended June 30, 2020. 
From Business Wire News Releases
Dicerna Announces Appointment of Shreeram Aradhye, M.D., as Executive Vice President and Chief Medical Officer
Dicerna announced the appointment of Shreeram Aradhye, M.D., as the Company’s executive vice president and chief medical officer, effective Sept. 8. 
From Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among seven employees. 
From Business Wire News Releases
Dicerna to Report Second Quarter 2020 Financial Results and Host Virtual Research and Development Event on Aug. 6, 2020
Dicerna announced that it will release its Q2 2020 financial results before market open on Thurs., Aug. 6 and will host a virtual R&D Day event. 
From Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among 15 employees. 
From Business Wire News Releases
Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria
Dicerna announced that the U.S. FDA has granted rare pediatric disease designation for nedosiran, which is in development for PH types 1, 2 and 3. 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.